MedTrace Logo

Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients

NCT06535529 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-08-05

No results posted yet for this study

Summary

The goal of this clinical trial is to compare the effectiveness of acetazolamide versus dapagliflozin as an add-on in treating acute decompensated heart failure (ADHF) in adult patients with clinical signs of volume overload requiring intravenous loop diuretics. It will also assess the safety of these drugs when added to standard care. The main questions it aims to answer are:

* Does acetazolamide or dapagliflozin lead to a greater reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels?
* Which drug results in better loop diuretic efficiency, as measured by weight loss per 40 mg of intravenous furosemide or equivalent? We will compare acetazolamide to dapagliflozin, both added to standard intravenous loop diuretic therapy, to see which is more effective in decongesting patients with ADHF.

Participants will:

* Take either acetazolamide or dapagliflozin orally every day for 3 days
* Receive intravenous loop diuretics as part of standard care
* Undergo regular assessments of heart failure symptoms, weight, and laboratory tests
* Be followed up until hospital discharge and for 30 days after starting the study

Conditions

  • Acute Decompensated Heart Failure

Interventions

DRUG

Acetazolamide

Patients will receive acetazolamide 500 mg once daily for 3 days as add on therapy to IV loop diuretics

DRUG

Dapagliflozin 10mg

patient will receive oral dapagliflozin 10 mg once daily for 3 days as add on therapy to IV loop diuretics

Sponsors & Collaborators

  • Helwan University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-24
Primary Completion
2025-08-01
Completion
2025-09-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06535529 on ClinicalTrials.gov